Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this is study is to assess the efficacy of pre-operative intravitreal
bevacizumab (IVB) (Genentech, South San Francisco CA) in improving visual acuity, reducing
operative time, complications, intra-operative and post-operative hemorrhage following small
gauge pars plana vitrectomy (PPV) (23-gauge, 25-gauge or 27-gauge ) compared to small gauge
PPV (23-gauge, 25-gauge or 27-gauge) alone in eyes with tractional retinal detachment (TRD)
secondary to proliferative diabetic retinopathy (PDR). Hypothesis: Preoperative IVB may be
beneficial for membrane dissection in diabetic tractional retinal detachment with minimally
invasive vitreoretinal surgery (23-gauge transconjunctival sutureless vitrectomy [TSV]). In
addition, post-operative rebleeding may be decreased.